You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

52 Results
Guidelines and Advice
Drug
Other Name(s): Vidaza®
Sep 2025
Drug
Other Name(s): Arimidex®
Updated
Dec 2025
Drug
Other Name(s): Trisenox®
Oct 2025
Drug
Other Name(s): Tagrisso®
Nov 2025
Drug
Other Name(s): Alecensaro®
Nov 2025
Drug
Other Name(s): Tecentriq™
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    osimertinib - For the treatment of locally advanced (not amenable to curative therapies) or metastatic non-small cell lung cancer (NSCLC), based on criteria
Exceptional Access Program
    osimertinib - For the treatment of locally advanced, unresectable (stage III) non-squamous non-small cell lung cancer (NSCLC), based on criteria
Nov 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to specific criteria
Dec 2025
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Avelumab - Metastatic Merkel Cell Carcinoma
Jan 2025
Drug
Other Name(s): Bavencio™
Jan 2025

Pages